A MedTech company on a mission to build a future where nobody dies of skin cancer has secured £15m in Series B funding led by Intrepid Growth Partners. This investment follows Skin Analytics’ recent EU MDR Class III CE mark approval, making its technology, DERM, the world’s first legally authorised AI medical device to independently … Continue reading MedTech looking to eliminate skin cancer fatalities raises £15m